-azenil
Drugs that act on the benzodiazepine site, either blocking or activating it.
- Drugs ending in -azenil: 20
- Approved somewhere: 5
- With a US drug page: 4
- Stem
- -azenil
- Class
- Drugs that act on the benzodiazepine site, either blocking or activating it
- Most common targets
- GABA-A receptor; anion channel (3), SLC6A3 (2), Bifunctional dihydrofolate reductase-thymidylate synthase (2), CHRM3 (1), CHRM1 (1), PTGIR (1), PGR (1), AKR1B1 (1)
Approved and clinical-stage drugs in ChEMBL whose names ending in -azenil or one of its sub-stems, matched by spelling; those with a US drug page link to it.
| Acts on | |||
|---|---|---|---|
| Flumazenil | Phase 2 | GABA-A receptor; anion channel | GABA-A receptor; anion channel allosteric antagonist |
| Iomazenil | Phase 1 | — | — |
| Gedocarnil | Phase 2 | — | — |
| Armodafinil | Approved | SLC6A3 | Dopamine transporter inhibitor |
| Diphemanil | Approved | CHRM3, CHRM1 | Muscarinic acetylcholine receptor M3 antagonist |
| Modafinil | Approved | SLC6A3 | Dopamine transporter inhibitor |
| Proguanil | Approved | Bifunctional dihydrofolate reductase-thymidylate synthase | Dihydrofolate reductase inhibitor |
| Treprostinil | Approved | PTGIR | Prostanoid IP receptor agonist |
| Asoprisnil | Phase 3 | PGR | Progesterone receptor modulator |
| Chlorproguanil | Phase 3 | — | — |
| Sorbinil | Phase 3 | AKR1B1 | Aldose reductase inhibitor |
| Adrafinil | Phase 2 | — | — |
| Basmisanil | Phase 2 | — | — |
| Cycloguanil | Phase 2 | Bifunctional dihydrofolate reductase-thymidylate synthase | Dihydrofolate reductase inhibitor |
| Emapunil | Phase 2 | TSPO | Translocator protein agonist |
| Padsevonil | Phase 2 | GABA-A receptor; anion channel, Synaptic vesicle protein | GABA-A receptor; anion channel partial agonist |
| Treprostinil palmitil | Phase 1 | — | — |
| Treprostinil phosphate | Phase 1 | — | — |
| Cyclofenil | — | ESR1, ESR2 | Estrogen receptor modulator |
| Resequinil | Phase 2 | GABA-A receptor; anion channel | GABA-A receptor; anion channel inverse agonist |
Stem from WHO, The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances (2024); description written by Arca. Drugs, stages, targets and mechanisms from ChEMBL (CC BY-SA 3.0). WHO